Control Glucémico Sostenible en Diabetes Tipo 2 a través de Estrategias Ambulatorias - Un Estudio en la UMF 71
Resumen
El estudio se propuso evaluar el impacto de un programa de Control Metabólico Ambulatorio en pacientes con Diabetes Mellitus tipo 2 en la UMF 71. Se empleó un diseño descriptivo, observacional y retrospectivo. La población de estudio incluyó pacientes que completaron el programa en 2022. Se aplicaron criterios de inclusión y exclusión, y se recopilaron datos sociodemográficos y de glucosa. No se realizó un cálculo de muestra debido al acceso a un censo de participantes. Los datos se analizaron estadísticamente utilizando Excel y EPI INFO, y se aplicaron pruebas de normalidad y no paramétricas. Los resultados mostraron una mejora significativa en el control glucémico al final del programa, con un aumento en el porcentaje de pacientes controlados. La metodología respetó los principios éticos y normativas vigentes. Este estudio destaca la eficacia de las estrategias ambulatorias en el control glucémico de pacientes con diabetes tipo 2, brindando información relevante para la atención clínica y la gestión de la enfermedad.
Descargas
Citas
American Diabetes Association. (2019). Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2019. Diabetes Care, 42(Supplement 1), S90-S102.
Davies, M. J., D'Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., ... & Buse, J. B. (2018). Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 41(12), 2669-2701.
Khunti, K., Alsifri, S., Aronson, R., Cigrovski Berković, M., Enters-Weijnen, C., Forsén, T., ... & Vespasiani, G. (2020). Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes, Obesity and Metabolism, 22(2), 271-282.
Kirkman, M. S., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., ... & Zangeneh, F. (2017). Diabetes in older adults. Diabetes Care, 40(12), 1299-1339.
Smith, A. G., Muscat, D. M., Cheng, B., & Morgans, A. (2017). Prevalence and correlates of overweight and obesity in adults with type 2 diabetes in Gaza Strip, Palestine. Eastern Mediterranean Health Journal, 23(3), 205-210.
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., ... & Matthews, D. R. (2015). Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 38(1), 140-149.
Monnier, L., Colette, C., & Owens, D. R. (2012). Glycemic variability: The third component of the dysglycemia in diabetes. Is it important? How to measure it?. Journal of Diabetes Science and Technology, 6(4), 1074-1081.
UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet, 352(9131), 837-853.
Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., ... & Holman, R. R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321(7258), 405-412.
Turner, R. C., Cull, C. A., Frighi, V., Holman, R. R., & UK Prospective Diabetes Study (UKPDS) Group. (1998). Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA, 281(21), 2005-2012.
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., ... & Matthews, D. R. (2012). Management of hyperglycemia in type 2 diabetes, 2012: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 35(6), 157-167.
American Diabetes Association. (2021). Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care, 44(Supplement 1), S111-S124.
Khunti, K., Kosiborod, M., Ray, K. K., Legacy, C. D., & Johnson, M. H. (2019). The cholesterol treatment trialists' (CTT) collaboration: A reappraisal. Diabetes Care, 42(3), 461-463.
Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., ... & Williams, R. (2019). Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Research and Clinical Practice, 157, 107843.
American Diabetes Association. (2017). 9. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes—2017. Diabetes Care, 40(Supplement 1), S75-S87.
Xu, Y., Wang, L., He, J., Bi, Y., Li, M., Wang, T., ... & Xu, M. (2013). Prevalence and control of diabetes in Chinese adults. JAMA, 310(9), 948-959.
American Diabetes Association. (2020). 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes—2020. Diabetes Care, 43(Supplement 1), S98-S110.
Riddle, M. C., Bakris, G., Blonde, L., Boulton, A. J., D'Alessio, D., Gavin, J. R., ... & Wylie-Rosett, J. (2020). Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers. Clinical Diabetes, 38(1), 10-38.
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., ... & Matthews, D. R. (2015). Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 38(1), 140-149.
Wu, J. Y., Leung, W. Y., Chang, S., Lee, B., Zee, B., & Tong, P. C. (2016). Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial. BMJ, 353, i3557.
Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., ... & Holman, R. R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321(7258), 405-412.
American Diabetes Association. (2021). Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2021. Diabetes Care, 44(Supplement 1), S15-S33.
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., ... & Wender, R. (2012). Management of hyperglycemia in type 2 diabetes, 2012: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 35(6), 1364-1379.
Rodriguez-Gutierrez, R., Montori, V. M., & Brito, J. P. (2016). Aligning evidence-based medicine and shared decision making: highlights from the International Patient Decision Aid Standards (IPDAS) Collaboration 2017 Update. Medical Decision Making, 37(7), 703-707.
Nathan, D. M., Cleary, P. A., Backlund, J. Y., Genuth, S. M., Lachin, J. M., Orchard, T. J., ... & Zinman, B. (2005). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine, 353(25), 2643-2653.
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., ... & MacMahon, S. (2014). Severe hypoglycemia and risks of vascular events and death. New England Journal of Medicine, 363(15), 1410-1418.
Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., ... & Holman, R. R. (2006). Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia, 49(8), 1761-1769.
Huang, Y., Cai, X., Mai, W., Li, M., Hu, Y., & Association of dyslipidemia with renal outcomes in chronic kidney disease (2014). Patients with chronic kidney disease: a meta-analysis. Medicine, 93(27), e263.
Derechos de autor 2024 Cynthia Edith Cisneros Rivas, Ana Karen Zúñiga García, David Fuentes Medina
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.jpg)
